Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
---|---|---|---|---|---|---|
Genentech | Vismodegib | Erivedge | 2025-09-02 | 2012-01-30 | ||
Horizon Therapeutics Public | Interferon gamma-1b | Actimmune | 1999-02-25 | $122.816 M | Q3/22-Q2/23 | |
Merck & Co | Interferon alfa-2b | Intron A | 1986-06-04 | |||
Interferon alfa-2b | IntronA | 2000-03-09 | ||||
Interferon alfa-2b | Viraferon | 2000-03-09 | ||||
Organon | Alendronate, Cholecalciferol | Fosamax D | 2005-04-07 | |||
Pharma& | Peginterferon alfa-2a | Pegasys | 2002-10-16 | |||
Roche | Vismodegib | Erivedge | 2013-07-12 | $303.263 M | Q4/22-Q3/23 | |
Ribavirin, Peginterferon alfa-2a | Pegasys Copegus | 2004-06-04 | ||||
Interferon alfa-2a | Roferon-A | 1986-06-04 | ||||
Sandoz | Folic acid, Dexpanthenol, Ascorbic acid, Cyanocobalamin, Vitamin a, Alpha-tocopherol, Biotin, Cholecalciferol, Niacinamide, Pyridoxine, Riboflavin, Thiamine, Tocopherol | Infuvite | 2000-05-18 | |||
Sun Pharmaceutical Industries | Sonidegib | Odomzo | 2029-07-24 | 2015-07-24 |
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
---|---|---|---|---|---|